Lab
Laboratorio Clinico Y Bacteriologico Gladyan INC.
Laboratorio Clinico Y Bacteriologico Gladyan INC. was paid $1.14M by Medicaid between Jan 2018 and Dec 2024, across 53 billing codes. Its largest line is 84443, Thyroid stimulating hormone (TSH) — 15% of everything it billed.
33Billing provider infoLABORATORIO CLINICO Y BACTERIOLOGICO GLADYAN INC.
YABUCOA, PR 00767
YABUCOA, PR 00767
33aNPI1750573200assigned 08/17/2007
33bProvider typeClinical Medical Laboratory
28Total paid$1.14M
24GClaims106,851
24DCodes billed53
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Clinical Medical Laboratory providers in Puerto Rico
Rank by total paid#104 of 777
Median peer was paid$278K
This provider vs. median4.1×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 21,381 | $158K | |
| 2019 | 14,750 | $108K | |
| 2020 | 9,275 | $98K | |
| 2021 | 13,172 | $172K | |
| 2022 | 13,495 | $181K | |
| 2023 | 13,773 | $165K | |
| 2024incomplete | 21,005 | $255K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 84443 | Thyroid stimulating hormone (TSH) | 15% | 9,934 | 9,030 | $173K |
| 80061 | Lipid panel | 14% | 11,149 | 10,133 | $154K |
| 80053 | Comprehensive metabolic panel | 11% | 11,377 | 10,206 | $124K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 9.7% | 16,136 | 14,151 | $111K |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | 7.2% | 1,899 | 1,697 | $82K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | 4.9% | 2,150 | 1,961 | $56K |
| 83036 | Hemoglobin; glycosylated (A1C) | 4.2% | 4,955 | 4,546 | $47K |
| 81000 | 3.6% | 12,584 | 11,273 | $41K | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | 2.9% | 2,991 | 1,395 | $33K |
| 86701 | 2.5% | 3,393 | 3,073 | $28K | |
| 82274 | 2.4% | 1,955 | 1,845 | $27K | |
| 84439 | 2.1% | 2,919 | 2,580 | $24K |
41 more codes
| 82607 | 2.0% | 1,753 | $23K | |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | 2.0% | 436 | $22K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | 1.9% | 654 | $21K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | 1.8% | 611 | $20K |
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | 1.5% | 709 | $17K |
| 82043 | 1.3% | 3,014 | $15K | |
| 80048 | Basic metabolic panel (calcium, ionized) | 1.2% | 1,749 | $14K |
| 86738 | 1.2% | 1,080 | $13K | |
| 87088 | 1.1% | 1,540 | $13K | |
| 86592 | 1.1% | 3,189 | $12K | |
| 86328 | <1% | 509 | $11K | |
| 84153 | <1% | 640 | $9K | |
| 84436 | <1% | 1,247 | $8K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 974 | $7K |
| 84479 | <1% | 1,006 | $6K | |
| 82951 | <1% | 424 | $5K | |
| 85027 | <1% | 766 | $4K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 1,981 | $4K |
| 82570 | <1% | 500 | $2K | |
| 85652 | <1% | 753 | $2K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 28 | $1K |
| 85730 | <1% | 231 | $1K | |
| 82950 | <1% | 151 | $960.53 | |
| 82947 | <1% | 285 | $913.91 | |
| 85610 | <1% | 286 | $866.46 | |
| 83655 | <1% | 59 | $710.56 | |
| 84703 | <1% | 93 | $651.89 | |
| 86038 | <1% | 42 | $377.63 | |
| 87177 | <1% | 74 | $311.48 | |
| G0328 | Colorectal cancer screening; fecal occult blood test, immunoassay, 1-3 simultaneous | <1% | 144 | $269.38 |
| 86803 | <1% | 13 | $196.75 | |
| 84460 | <1% | 87 | $195.47 | |
| 84450 | <1% | 87 | $190.68 | |
| 86140 | <1% | 47 | $183.17 | |
| 86430 | <1% | 41 | $163.58 | |
| 87186 | <1% | 21 | $153.20 | |
| 85651 | <1% | 102 | $151.64 | |
| 82042 | <1% | 35 | $124.07 | |
| 84550 | <1% | 24 | $88.40 | |
| 83540 | <1% | 12 | $74.04 | |
| G0103 | Prostate cancer screening; prostate specific antigen test (psa) | 0% | 12 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialTORRES-AZIZE, JOSE (GENERAL MANAGER)